Home・Listă Acțiuni・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Deschisă

SectorSănătate

39.07 4.27

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

37.29

Maxim

39.07

Indicatori cheie
By Trading Economics
Venit	2.6M -79M
Vânzări	-60K 15K
EPS	-1.18
Marjă de profit	-524,566.667
Angajați	198
EBITDA	2.7M -78M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+51.02% upside

Dividende
By Acuity
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	226M 2.8B
Deschiderea anterioară	34.8
Închiderea anterioară	39.07

Sentimentul știrilor

By Acuity

50%

151 / 340 Clasament în Healthcare

Celldex Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 aug. 2026, 19:53 UTC

Celldex Therapeutics Inc. shares are lower as biotechnology stocks decline. The broader sector's weakness has influenced the stock's price action today.

31 iul. 2026, 19:36 UTC

Celldex Therapeutics Inc. shares are lower today amid significant pressure on biotechnology stocks, with no specific company news identified to explain the decline.

30 iul. 2026, 18:51 UTC

Celldex Therapeutics Inc is advancing during Thursday's session, moving higher alongside the broader market amid positive macroeconomic sentiment.

29 iul. 2026, 20:03 UTC

Macro Event

News

Wells Fargo raised its price target on Celldex Therapeutics to $72, citing confidence in the company's growth prospects and promising pipeline. Shares are higher today.

28 iul. 2026, 19:36 UTC

Shares of Celldex Therapeutics Inc. are lower today, continuing a decline since Monday's close, despite an earlier modest rebound from session lows.

27 iul. 2026, 19:31 UTC

News

Celldex Therapeutics is higher today, bolstered by strong sentiment for its barzolvolimab program and successful Phase 3 enrollment for chronic spontaneous urticaria trials.

22 iul. 2026, 20:01 UTC

Event

News

Social Media

Celldex Therapeutics is lower after discontinuing barzolvolimab development due to failed trial results. Wells Fargo lowered its price target to $48.

21 iul. 2026, 23:01 UTC

Social Media

Event

News

Celldex Therapeutics shares fell in after-market hours following disappointing Phase 2 trial results for barzolvolimab, which failed to meet primary and secondary endpoints.

Comparație

Modificare preț

Celldex Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

51.02% sus

Prognoză pe 12 luni

Medie 56.92 USD 51.02%

Maxim 100 USD

Minim 34 USD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCelldex Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

14 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 14 analiști care au acordat evaluări ale acțiunilor Celldex Therapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

151 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.